DOI: https://doi.org/10.24959/ophcj.19.959

The synthesis and the study of the antitumor activity of 1,4-diaryl-5,6,7,8-tetrahydro-2,2a,8a triazacyclopenta[cd]azulene derivatives

S. A. Demchenko, Yu. A. Fedchenkova, L. S. Bobkova, L. P. Artemchuk, A. M. Demchenko

Abstract


Aim. To synthesize, prove the structural framework and study the antitumor activity of 1,4-diaryl-5,6,7,8-tetrahydro-2,2a,8a-triazacyclopenta [cd]azulene derivatives.

Results and discussion. To determine the antineoplastic activity of 1-phenyl-4-aryl-5,6,7,8-tetrahydro-2,2a,8a-triazacyclopenta[cd]azulenes 7a-g and 1-(41-bromophenyl)-4-aryl-5,6,7,8-tetra-hydro-2,2a,8a-triazacyclopenta [cd]azulenes 7h-k the study in vitro was carried out on 60 lines of cancer cells (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer) under the effect of the substance in the concentration of 10-5 mol/l according to the standard procedure of the mitotic activity assessment of the new potential bioactive compounds by the fluorescent coloring method (sulphorhodamine B as a dye) performed in the US National Institute of cancer within the Development Therapeutic Program.

Experimental part. 2-Methoxy-3,4,5,6-tetrahydro-7H-azepine was obtained by alkylation of caprolactam with dimethyl sulfate. 3-Phenyl or (41-bromophenyl)-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine 4 a,b was obtained by condensation of 2-methoxy-3,4,5,6-tetrahydro-7H-azepine 1 with 4-bromobenzoic acid hydrazide and subsequent cyclization of the intermediate product. The 1Н-NMR spectra were recorded on a Bruker VXR-300 spectrometer (Germany) with the working frequency of 299.945 MHz, in DMSO-d6 using tetramethylsilane (TMS) as an internal standard. The purity of the compounds synthesized was controlled by TLC on the Silufol UV-254 plates in the system of chloroform – methanol (9 : 1).

Conclusions. New chemical compounds – derivatives of 1-phenyl(41-bromphenyl)-4-aryl-5,6,7,8-tetrahydro-2,2a,8a-triaza-cyclopenta[cd]azulene have been synthesized. The anticancer activity of the compounds obtained on 60 lines of tumor cells in the US National Cancer Institute has been studied. The high-active compounds that exhibit high levels of the antitumor activity have been identified.


Keywords


1,4-diaryl-5,6,7,8-tetrahydro-2,2a,8a-triazacyclopenta[cd]azulenes; antitumor activity

Full Text:

PDF

References


Teregulova, D. R., Bakirov, B. A., & Akhmadeeva, L. R. (2018). Influence of polychemotherapy on cognitive functions in patients with lymphoproliferative diseases : literature review and personal clinical observations. Perm Medical Journal, 35 (6), 73–81. https://doi.org/10.17816/pmj35673-81

Gorbunova, T. V., Abdulrahman Ali, A.–A. G., Glekov, I. V., Susuleva, N. A., Shishkov, R. V., Ivanova, N. V., & Polyakov, V. G. (2018). Analysis of Treatment of the Outcomes in Pediatric Patients With Nasopharyngeal Cancer: A Retrospective Cohort Study. Oncopediatrics, 5 (4), 257–267. https://doi.org/10.15690/onco.v5i4.1969

Protipuhlinnі zasobi. DMUPharm. Non scholae, sed vitae discimus. Available at: http://dmupharm.pp.ua/index.php/temi/20-khimioterapevtichni-zasobi-riznikh-grup/228protipukhlinni-zasobi

Kravchenko, T. V., Panasenko, O. І., Knish, Ye. G. (2016). Farmacevtichnij zhurnal, 5, 25–30.

Mouridsen, H. Giobbie–Hurder, A., Goldhirsch A., Thürlimann B., Paridaens R, Smith I, Coates, A. S. (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. The New England Journal of Medicine, 361 (8), 766–776. https://doi.org/10.1056/nejmoa0810818

Slomovitz, B. M., Taub, M. C., Huang, M., Levenback, C., & Coleman, R. L. (2019). A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). Gynecologic Oncology Reports, 27, 1–4. https://doi.org/10.1016/j.gore.2018.11.001

The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group (2003). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early–stage breast cancer. Cancer, 98(9), 1802–1810. https://doi.org/10.1056/nejmoa0810818

Povoroznyuk, V. V., Bystrytska, M. A., & Musiienko, A. S. (2018). Osteoporosis in oncology. PAIN. JOINTS. SPINE, 8 (2), 101–110. https://doi.org/10.22141/2224-1507.8.2.2018.137192

“World Cancer Report”. (2008). International Agency for Research on Cancer. Retrieved 2011–02–26. (cancer statistics often exclude non-melanoma skin cancers such as basal cell carcinoma, which are common but rarely fatal). URL: https://www.who.int/cancer/publications/world_cancer_report2008/en/

Beverly A. Teicher, Paul A. Andrews. (Eds). (2004). Anticancer drug development guide: preclinical screening, clinical. Medical, 1, 450.

Alley M.C, Scudiero, D. A., Monks, P. A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., Boyd, M. R. (1988). Feasibility of drug screening with panels of human tumor cell lines using a microculture Tetrazolium assay. Cancer Res, 48, 589–601.

Carter, P. H., Scherle, P. A., Muckelbauer, J. A., Voss, M. E., Liu, R.-Q., Thompson, L. A., … Decicco, C. P. (2001). Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF. Proceedings of the National Academy of Sciences, 98 (21), 11879–11884. https://doi.org/10.1073/pnas.211178398

Grever, M. R., Schepartz, S. A., Chabner, B. A. (1992). The National Cancer Institute : cancer drug discovery and development program. Seminars in Oncol, 19 (6), 622–638.

Granik, V. G., Zhidkova, A. M., Kuryatov, N. (1973). HGS, 11, 1532–1535.

Petersen, S., & Tietze, E. (1957). Reaktionen Cyclischer Lactimäther mit Acylierten Hydrazinderivaten. Chemische Berichte, 90 (6), 909–921. https://doi.org/10.1002/cber.19570900609


GOST Style Citations


1.         Терегулова, Д. Р. Влияние полихимиотерапии на когнитивные функции у пациентов с лимфопролиферативными заболеваниями: обзор литературы и собственные клинические наблюдения / Д. Р. Терегулова, Б. А. Бакиров, Л. Р. Ахмадеева // Пермский медицинский журн. – 2018. – Т. 35, № 6. – С. 73–81. https://doi.org/10.17816/pmj35673-81

 

2.         Анализ результатов лечения пациентов детского возраста с раком носоглотки: ретроспективное когортное исследование / Т. В. Горбунова, Али А. Абдулрахман, И. В. Глеков и др. // Онкопедиатрия. – 2018. – № 5 (4). – С. 257–267. https://doi.org/10.15690/onco.v5i4.1969

 

3.         Протипухлинні засоби. [Електронний ресурс] // DMUPharm. Non scholae, sed vitae discimusa. – Режим доступу : http://dmupharm.pp.ua/index. php/temi/20-khimioterapevtichni-zasobi-riznikh-grup/228-protipukhlinni-zasobi.

 

4.         Кравченко, Т. В. Біологічна активність похідних 1,2,4–триазолу / Т. В. Кравченко, О. І. Панасенко, Є. Г. Книш // Фарм. журн. – 2016. – № 5. – С. 25–30.

 

5.         Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer / H. Mouridsen, A. Giobbie–Hurder, A. Goldhirsch et al. // Engl. J. Med. – 2009. – Vol. 361 (8). – Р. 766–776. https://doi.org/10.1056/nejmoa0810818 

 

6.         A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS) / M. B. Slomovitza, M. C. Tauba, M. Huanga et al. // Gynecologic Oncology Reports. – 2019. – Vol. 27. – P. 1–4. https://doi.org/10.1016/j.gore.2018.11.001

 

7.         Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses / The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group // Howell Cancer. – 2003. – Vol. 98. – Р. 1802–1810. https://doi.org/10.1056/nejmoa0810818 

 

8.         Поворознюк, В. В. Остеопороз при злоякісних новоутвореннях / В. В. Поворознюк, М. А. Бистрицька, А. С. Мусіенко // Боль. Суставы. Позвоночник. – 2018. – № 8 (2). С. 101–110. https://doi.org/10.22141/2224-1507.8.2.2018.137192

9.         “World Cancer Report”. [Електронний ресурс] : / International Agency for Research on Cancer. – 2008. – Режим доступу : https://www.who.int/cancer/publications/world_cancer_report2008/en/

10.       Beverly, A. Andrews. Anticancer drug development guide : preclinical screening, clinical / A. Beverly, P. A. Teicher // Medical. – 2004. – 450 p.

 

11.       Feasibility of drug screening with panels of human tumor cell lines using a microculture Tetrazolium assay / M. C. Alley, D. A. Scudiero, P. A. Monks et al. // Cancer Res. –1988. – Vol. 48. – P. 589–601.

 

12.       Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor–1 inhibits the binding of TNF–α / P. H. Carter, P. A. Scherle, J. A. Muckelbauer et al. // Proc. Natl. Acad. Sci. USA. – 2001. – Vol. 98. – P. 11879–11886. https://doi.org/10.1073/pnas.211178398 

 

13.       Grever, M. R. The National Cancer Institute : cancer drug discovery and development program / M. R. Grever, S. A. Schepartz, B. A. Chabner // Seminars in Oncol. – 1992. – Vol. 19, № 6. – P. 622–638.

 

14.       Ацетали лактамов. VII. Исследование алкилирования N-метиллактамов и лактимных эфиров диметилсульфатом // В. Г. Граник, А. М. Жидкова, Н. С. Курятов и др. // ХГС. – 1973. – № 11. – С. 1532–1535.

 

15.       Siegfried Petersen and Ernst Tietze. Reaktionen Cyclischer Lactimäther mit Acylierten Hydrazinderivaten // Chem. Ber. – 1957. – Vol. 90., Issue 6. – P. 909–921. https://doi.org/10.1002/cber.19570900609 





Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Ž. org. farm. hìm.

ISSN 2518-1548 (Online), ISSN 2308-8303 (Print)